Medtronic stock
Price history
+7.48% over the period1 year: from $96.28 (November 17, 2025) to $103.49 (November 16, 2026), +7.48%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $103.49 |
| October 30, 2026 | $96.54 |
| September 30, 2026 | $86.29 |
| August 31, 2026 | $90.65 |
| July 31, 2026 | $85.39 |
| June 30, 2026 | $78.23 |
| May 29, 2026 | $73.81 |
| April 30, 2026 | $80.97 |
| March 31, 2026 | $86.65 |
| February 27, 2026 | $97.66 |
| January 30, 2026 | $102.96 |
| December 31, 2025 | $96.06 |
| November 28, 2025 | $105.33 |
| November 17, 2025 | $96.28 |
At a glance
The company
Develops and manufactures implantable cardiac devices, neurostimulation systems, and surgical instruments for healthcare providers and patients worldwide
Latest results
Quarter to July 31, 2026 · EPS $1.45 (estimate $1.39)
Next event
TickerLandia's take on Medtronic
- Priced as usual relative to earnings: P/E on the latest fiscal year 28 vs a median of 28 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 25 vs 31 (−19%) in a group of 11.
- Strong point: Dividend (83/100 in its group). Weak point: Financial strength (38/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.68% from the 52-week high
Analysts · 30 analysts
Average target$105.00+1.46% vs. price
Buy 19 · Hold 11 · Sell 0 · Buy
TickerLandia Fingerprint: Medtronic
Compared with similar companies: very high dividend.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow38
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 25.3 29 Price/sales 3.50 60 Forward P/E 16.1 28 EV/EBITDA 14.6 38 Price/book 2.62 34 Profitabilityaverage55
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 65.3% 50 Operating margin 20.1% 76 ROA 5.1% 31 Net margin 13.9% 76 ROE 10.6% 40 Earnings stabilityhigh77
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 0.9% 98 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthhigh60
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +13.70% 71 Earnings growth (year over year) +40.70% 69 Average revenue growth (3 years) +5.21% 40 Financial strengthlow38
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.69 12 Debt/equitycounts in reverse: lower means more financial strength 0.55 47 Current ratio 2.07 56 Interest coverage 10.2 38 Dividendvery high83
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 96 Dividend yield 2.8% 83 Payout ratio 70.3% 70 Market momentumstrong75
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +17.12% 88 1-year return +6.99% 41 Relative strength (6 months) +32.87% 88 Distance from 200-day average +16.54% 83 Risklow36
How much the price swings.
Metric Value Position in group Volatility (60 days) 27.3% 31 Beta (1 year) 0.15 24 Maximum drawdown (12 months) 30.0% 52
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Medtronic is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), Medtronic's P/E today is 27.7, in line with the median of its last 10 fiscal years (28.4; between 22.3 and 49.2 from 2017 to 2026). Medtronic's P/E (trailing 12 months): 25.4, −19% against the median of a group of 11 similar companies (31.4).
Compared with 11 similar companies
| Metric | Medtronic | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 25.4 | Middle | |
| Forward P/E | 16.1 | Middle | |
| Operating margin | 20.1% | Middle | |
| ROE | 10.6% | Middle | |
| Debt/equity | 0.55 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Medtronic. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$9.76B
Latest quarter · Q to Jul 2026
Net income
$1.47B
Latest quarter · Q to Jul 2026
Quarterly net margin
15.1%
Latest quarter · Q to Jul 2026
Numbers and valuation
Full valuation- Market cap
- $132.22B
- P/E
- 25.4
- EPS
- $4.07
- Volume
- 1.22M
- Daily trading
- €789.75M
- Dividend yield
- 2.76%
- Last ex-dividend on September 25, 2026
How Medtronic is changing
All resultsRevenue grew 3.8% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 120% of net income
Shares outstanding down 4.9% in 5 years
Returns
Medtronic returns with dividends
$1,000 invested in Medtronic 5 years ago, on November 16, 2021, would be worth $1,029 today with dividends reinvested: +2.90% in total, +0.57% per year. On price alone it would be $877 (−12.29%).
| Period | Medtronic | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +9.22% | −3.12% | $1,092 |
| 6 months | +35.90% | +2.07% | $1,359 |
| Year to date | +7.73% | +10.46% | $1,077 |
| 1 year | +11.02% | +13.33% | $1,110 |
| 3 years | +52.43% | +67.73% | $1,524 |
| 5 years | +2.90% | +60.86% | $1,029 |
| 10 years | +66.52% | +247.35% | $1,665 |
Over the last 6 months it has done better than 72% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Medtronic: technical analysis
Medtronic shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 23.4% below its highest close since January 2, 1990 ($135.17, September 8, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 65
- Between 30 and 70
- vs 200-session average
- +17.25%
Support and resistance
Price areas where Medtronic has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$106.01+2.44%3 touches, last on November 5, 2026
- Last price$103.49
- Support$95.20−8.01%6 touches, last on September 15, 2026
- Support$89.44−13.57%5 touches, last on September 11, 2026
- Support$85.34−17.53%5 touches, last on October 1, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.15
- Volatility (60 sessions, annualised)
- 27.3%
- Largest fall in the last year
- −30.00%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Medtronic: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Medtronic has been December: +2.30% on average, positive in 22 years out of 36. The weakest has been February: −1.36% on average, positive in 16 years out of 37. November, the current month, has been positive in 22 years out of 36 (+2.24% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.14% | +1.05% | 21 of 36 |
| February | −1.36% | −1.06% | 16 of 37 |
| March | −0.08% | +0.41% | 20 of 37 |
| April | +0.17% | −0.11% | 18 of 37 |
| May | +2.08% | +1.68% | 25 of 37 |
| June | +0.95% | +0.90% | 19 of 37 |
| July | +1.63% | +2.09% | 25 of 37 |
| August | +1.55% | +3.15% | 24 of 37 |
| September | +1.00% | +0.68% | 19 of 37 |
| October | +0.87% | +0.26% | 19 of 37 |
| November | +2.24% | +2.14% | 22 of 36 |
| December | +2.30% | +2.37% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Medtronic and its competitors
Headquartered in Galway, Ireland, Medtronic plc was founded in 1949 and sells medical technology across three areas. Its cardiovascular range includes pacemakers, defibrillators, heart valves, and remote monitoring software, while its neuroscience offering covers spinal cord stimulation, brain modulation, and implantable drug infusion systems. The medical and surgical portfolio spans surgical stapling, robotic-assisted surgery, hernia and gynecology products, and insulin pumps with continuous glucose monitoring.
- Headquarters
- Galway, Ireland
- Employees
- 95,000
- Founded
- 1949
- Chief executive
- Geoffrey Martha
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MedtronicMDT | $132.22B | 20.1% | 25.4 | +35.90% |
| StrykerSYK | $117.88B | 24.0% | 33.0 | +1.41% |
| Abbott LaboratoriesABT | $187.95B | 15.6% | 40.5 | +28.26% |
| Boston ScientificBSX | $64.27B | 19.6% | 18.7 | −16.65% |
| Edwards LifesciencesEW | $61.61B | 28.8% | 61.6 | +31.31% |
| GE HealthCare TechnologiesGEHC | $37.8B | 13.8% | 17.7 | +37.99% |
Same industry or related industries, similar size. Compare Medtronic with its competitors · Full profile
